一项HMPL-760联合R-GemOx对比安慰剂联合R-GemOx治疗复发/难治性DLBCL的III期研究
一项评估HMPL-760联合R-GemOx对比安慰剂联合R-GemOx在复发/难治性弥漫性大B细胞淋巴瘤(DLBCL)患者中的疗效、安全性和药代动力学的III期随机、双盲、阳性对照研究
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
研究概览
详细说明
The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.
The target population of this study includes patients with DLBCL who are relapsed or refractory.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Dongmei Chen, CPL
- 电话号码:86-21-20671794
- 邮箱:dongmeic@hutch-med.com
学习地点
-
-
-
Baoding、中国
- 招聘中
- Baoding NO.1 Central Hospital
-
接触:
- Haiying Yao
- 电话号码:18617789030
- 邮箱:haiyingyaobd@163.com
-
首席研究员:
- Haiying Yao
-
Beijing、中国
- 招聘中
- Beijing GoBroad Hospital
-
首席研究员:
- Kai Hu
-
接触:
- Kai Hu
- 电话号码:15010390336
- 邮箱:HK13610956245@163.com
-
Beijing、中国
- 招聘中
- BEIJING TONGREN HOSPITAL, Capital Medical University
-
首席研究员:
- Liang Wang
-
接触:
- Liang Wang
- 电话号码:15001108693
- 邮箱:wangliangtrhos@126.com
-
Bengbu、中国
- 招聘中
- The First Affiliated Hospital of Bengbu Medical College
-
接触:
- Yanli Yang
- 电话号码:13855249678
- 邮箱:Yangyanli0702@126.com
-
首席研究员:
- Yanli Yang
-
Changchun、中国
- 招聘中
- The First Hospital of Jilin University
-
首席研究员:
- Ou Bai
-
接触:
- Ou Bai
- 电话号码:13039046656
- 邮箱:lbl2054@163.com
-
Changsha、中国
- 招聘中
- Hunan Cancer Hospital
-
首席研究员:
- Hui Zhou
-
接触:
- Hui Zhou
- 电话号码:13975879796
- 邮箱:zhouhui9403@126.com
-
Changsha、中国
- 招聘中
- The Second Xiangya Hospital of Central South University
-
首席研究员:
- Hongling Peng
-
接触:
- Hongling Peng
- 电话号码:18900766137
- 邮箱:Penghongling@aliyun.com
-
Changsha、中国
- 招聘中
- People's Hospital of Hunan Province
-
接触:
- Can Liu
- 电话号码:137 8728 5260
- 邮箱:617170469@qq.com
-
首席研究员:
- Can Liu
-
Chengdu、中国
- 招聘中
- West China Hospital of Sichuan University
-
首席研究员:
- Liqun Zou
-
接触:
- Liqun Zou
- 电话号码:18980601027
- 邮箱:Clinical_Zou@163.com
-
Chengdu、中国
- 招聘中
- Sichuan Provincial People's Hospital
-
接触:
- Xiaobing Huang
- 电话号码:18981838236
- 邮箱:hxb_trial@163.com
-
首席研究员:
- Xiaobing Huang
-
Chongqing、中国
- 招聘中
- The First Affiliated Hospital of Chongqing Medical University
-
首席研究员:
- Xin Wang
-
接触:
- Xin Wang
- 邮箱:925170788@qq.com
-
Chongqing、中国
- 招聘中
- Chongqing University Cancer Hospital
-
首席研究员:
- Yao Liu
-
接触:
- Yao Liu
- 邮箱:liuyao101709@163.com
-
Fujian、中国
- 招聘中
- Quanzhou First Hospital.Fujian
-
接触:
- Xiongpeng Zhu
- 电话号码:13805998581
- 邮箱:xiongpengzhu@163.com
-
首席研究员:
- Xiongpeng Zhu
-
Fuzhou、中国
- 招聘中
- Fujian Medical University Union Hospital
-
首席研究员:
- Jianzhen Shen
-
接触:
- Jianzhen Shen
- 电话号码:138 0955 2722
- 邮箱:doctorsjz@163.com
-
Guangzhou、中国
- 招聘中
- Sun Yat-sen University Cancer Center
-
首席研究员:
- Zhiming Li
-
接触:
- Zhiming Li
- 电话号码:13719189172
- 邮箱:lzmsysu@163.com
-
Guangzhou、中国
- 招聘中
- Guangdong Provincial People's Hospital
-
接触:
- Xiaojuan Wei
- 电话号码:86 13560097145
- 邮箱:jxw919@hotmail.com
-
首席研究员:
- Xiaojuan Wei
-
Guangzhou、中国
- 招聘中
- ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
-
首席研究员:
- Yuhua Li
-
接触:
- Yuhua Li
- 电话号码:13533706656
- 邮箱:liyuhua2011gz@163.com
-
Guiyang、中国
- 招聘中
- The Affiliated Hospital of Guizhou Medical University
-
首席研究员:
- Yan Zhang
-
接触:
- Yan Zhang
- 电话号码:86 18984155172
- 邮箱:Zhangyan20010802@sina.com
-
Hangzhou、中国
- 招聘中
- Zhejiang Cancer Hospital
-
首席研究员:
- Haiyan Yang
-
接触:
- Haiyan Yang
- 邮箱:2054451461@qq.com
-
Hangzhou、中国
- 招聘中
- The First Affiliated Hospital, Zhejiang University
-
首席研究员:
- Zhen Cai
-
接触:
- Zhen Cai
- 电话号码:13857190311
- 邮箱:czclinicaltrial@163.com
-
Harbin、中国
- 招聘中
- Harbin Medical University Cancer Hospital
-
接触:
- Qingyuan Zhang
- 电话号码:13313612989
- 邮箱:sy86298276@163.com
-
首席研究员:
- Qingyuan Zhang
-
Hefei、中国
- 招聘中
- The Second Affiliated Hospital of Anhui Medical University
-
接触:
- Zhimin Zhai
- 电话号码:13855147434
- 邮箱:zzzm889@163.com
-
首席研究员:
- Zhimin Zhai
-
Jinan、中国
- 招聘中
- Qilu Hospital of Shandong University
-
接触:
- Shuqian Xu
- 电话号码:18560087013
- 邮箱:yoyoshuqian@126.com
-
首席研究员:
- Shuqian Xu
-
Jinan、中国
- 招聘中
- Shandong Cancer Hospital & Institute
-
首席研究员:
- Zengjun Li
-
接触:
- Zengjun Li
- 电话号码:15735178591
- 邮箱:zengjunli@163.com
-
Kunming、中国
- 尚未招聘
- The First Affiliated Hospital of Kunming Medical University
-
接触:
- Mingxia Shi
- 电话号码:86 138 8806 0581
- 邮箱:shmxia2002@sina.com
-
首席研究员:
- Mingxia Shi
-
Nanchang、中国
- 招聘中
- Jiangxi Cancer Hospital
-
首席研究员:
- Yan Huang
-
接触:
- Yan Huang
- 邮箱:29265061@qq.com
-
Nanjing、中国
- 招聘中
- Jiangsu Cancer Hospital
-
首席研究员:
- Yan Zhang
-
接触:
- Yan Zhang
- 电话号码:13914712395
- 邮箱:zhangyan1106@njmu.edu.cn
-
Nanjing、中国
- 招聘中
- Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
-
接触:
- Jingyan Xu
- 电话号码:86 13951969610
- 邮箱:xjy1967@sina.com
-
首席研究员:
- Jingyan Xu
-
Nanning、中国
- 招聘中
- The First Affiliated Hospital of Guangxi Medical University
-
首席研究员:
- Zhigang Peng
-
接触:
- Zhigang Peng
- 邮箱:2557382235@qq.com
-
Qingdao、中国
- 招聘中
- The Affiliated Hospital of Qingdao University
-
接触:
- Xia Zhao
- 电话号码:18661803088
- 邮箱:Zhaoxia@qdu.edu.cn
-
首席研究员:
- Xia Zhao
-
Shanghai、中国
- 招聘中
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
首席研究员:
- Weili Zhao
-
接触:
- Weili Zhao
- 电话号码:86 13512112076
- 邮箱:zwl_trial@163.com
-
Shanghai、中国
- 招聘中
- Tongji Hospital of Tongji University
-
接触:
- Ping Li
- 电话号码:13564181131
- 邮箱:lilyforever76@126.com
-
首席研究员:
- Ping Li
-
Shanghai、中国
- 尚未招聘
- Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
-
首席研究员:
- Ligen Liu
-
接触:
- Ligen Liu
- 电话号码:86 18017337037
- 邮箱:llg3532@shtrhospital.com
-
Shenyang、中国
- 招聘中
- Shengjing Hospital of China Medical University
-
首席研究员:
- Wei Yang
-
接触:
- Wei Yang
- 电话号码:18940251012
- 邮箱:sjyangw@163.com
-
Shenzhen、中国
- 招聘中
- Shenzhen people's hospital
-
首席研究员:
- Jihao Zhou
-
接触:
- Jihao Zhou
- 电话号码:86 18718678693
- 邮箱:zhoujihao@aliyun.com
-
Taiyuan、中国
- 招聘中
- Shanxi Provincial Cancer Hospital
-
首席研究员:
- Liping Su
-
接触:
- Liping Su
- 电话号码:13835158122
- 邮箱:slpsy2022@163.com
-
Tangshan、中国
- 招聘中
- North China University of Science and Technology Affiliated Hospital
-
接触:
- Zhenyu Yan
- 电话号码:15931508262
- 邮箱:hbyzy2011@163.com
-
首席研究员:
- Zhenyu Yan
-
Tianjin、中国
- 招聘中
- Tianjin Medical University Cancer Institute & Hospital
-
首席研究员:
- Zhengzi Qian
-
接触:
- Zhengzi Qian
- 电话号码:13702031222
- 邮箱:qzz@163.com
-
Tianjin、中国
- 招聘中
- Tianjin People's Hospital
-
接触:
- Xingli Zhao
- 电话号码:13752255454
- 邮箱:insectzhao@163.com
-
首席研究员:
- Xingli Zhao
-
Tianjin、中国
- 招聘中
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
首席研究员:
- Dehui Zou
-
接触:
- Dehui Zou
- 电话号码:13602100955
- 邮箱:zoudehui@ihcams.ac.cn
-
Wenzhou、中国
- 招聘中
- The First Affiliated Hospital of WMU
-
接触:
- Songfu Jiang
- 电话号码:86 15305770033
- 邮箱:jiangsongfu@189.cn
-
首席研究员:
- Songfu Jiang
-
Wuhan、中国
- 招聘中
- Hubei Cancer Hospital
-
首席研究员:
- Huijing Wu
-
接触:
- Huijing Wu
- 邮箱:3269614878@qq.com
-
Wuhan、中国
- 招聘中
- Wuhan Union Hospital of China
-
首席研究员:
- Liling Zhang
-
接触:
- Liling Zhang
- 电话号码:15871725926
- 邮箱:lily1228@sina.com
-
Xi'an、中国
- 招聘中
- The First Affiliated Hospital of Xi'an Jiaotong University
-
首席研究员:
- Pengcheng He
-
接触:
- Pengcheng He
- 电话号码:18991232609
- 邮箱:hepc_gcp@163.com
-
Xi'an、中国
- 招聘中
- The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
-
首席研究员:
- Jie Liu
-
接触:
- Jie Liu
- 电话号码:86 18092662371
- 邮箱:lieujie@163.com
-
Xiamen、中国
- 尚未招聘
- The First Affiliated Hospital of Xiamen University
-
首席研究员:
- Bing Xu
-
接触:
- Bing Xu
- 电话号码:86 18750918842
- 邮箱:xubingzhangjian@126.com
-
Xuzhou、中国
- 招聘中
- The Affiliated Hospital of Xuzhou Medical University
-
接触:
- Wei Sang
- 电话号码:86 13645207648
- 邮箱:13645207648@126.com
-
首席研究员:
- Wei Sang
-
Zhengzhou、中国
- 招聘中
- Henan Cancer Hospital
-
首席研究员:
- Keshu Zhou
-
接触:
- Keshu Zhou
- 电话号码:13674902391
- 邮箱:dr_zkshu23810@163.com
-
Zhengzhou、中国
- 招聘中
- The First Affiliated Hospital of Zhengzhou University
-
接触:
- Xudong Zhang
- 电话号码:13633825183
- 邮箱:feverxxd@126.com
-
首席研究员:
- Xudong Zhang
-
Ürümqi、中国
- 招聘中
- People's Hospital of Xinjiang Uygur Autonomous Region
-
首席研究员:
- Yan Li
-
接触:
- Yan Li
- 电话号码:86 13639935315
- 邮箱:liyan232917@139.com
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国
- 招聘中
- Fudan University Shanghai Cancer Center
-
接触:
- Fangfang Lv
- 电话号码:18017312613
- 邮箱:Lvff80@163.com
-
首席研究员:
- Fangfang Lv
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Sign the ICF and be able to follow the requirements of study protocol;
- Age ≥18 years;
- ECOG performance status score between 0 and 2;
- Histopathologically confirmed diagnosis of DLBCL;
- The investigator judges that the patient's current condition requires further treatment;
- Patients should have at least one bi-dimensionally measurable lesion;
- Expected survival is more than 12 weeks;
Exclusion Criteria:
- Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
- Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
- Organ insufficiency;
- Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
- History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
- Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
- The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
- Clinically significant active infection;
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:The experimental group
Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle. |
Patients will receive HMPL-760 once daily (QD) orally. R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
其他名称:
|
|
安慰剂比较:The control group
Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group. |
R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
其他名称:
Patients will receive HMPL-760 placebo once daily (QD) orally. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free survival (PFS)
大体时间:Up to approximately two years
|
Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first. |
Up to approximately two years
|
|
End of treatment (EOT)
大体时间:Up to approximately two years
|
Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy). |
Up to approximately two years
|
|
Systemic antitumor therapy
大体时间:Up to approximately two years
|
Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy). |
Up to approximately two years
|
|
Overall survival (OS)
大体时间:Up to approximately two years
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately two years
|
|
systematic anti-tumor therapy
大体时间:Up to approximately two years
|
OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
|
Premature withdrawal from study treatment
大体时间:Up to approximately two years
|
OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Independent review committee (IRC)-assessed PFS
大体时间:Up to approximately two years
|
Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). |
Up to approximately two years
|
|
IRC- and investigator-assessed objective response rate (ORR)
大体时间:Up to approximately two years
|
Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) |
Up to approximately two years
|
|
IRC- and investigator-assessed complete response rate (CRR)
大体时间:Up to approximately two years
|
Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR) |
Up to approximately two years
|
|
IRC- and investigator-assessed duration of response (DoR)
大体时间:Up to approximately two years
|
For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first |
Up to approximately two years
|
|
IRC- and investigator-assessed clinical benefit rate (CBR)
大体时间:Up to approximately two years
|
Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD) |
Up to approximately two years
|
|
IRC- and investigator-assessed time to response (TTR)
大体时间:Up to approximately two years
|
Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR) |
Up to approximately two years
|
|
Safety Endpoints
大体时间:Up to approximately two years
|
|
Up to approximately two years
|
|
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
大体时间:At the end of Cycle 4 (each cycle is 21 days)]
|
including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. |
At the end of Cycle 4 (each cycle is 21 days)]
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Biomarker assessment
大体时间:Up to approximately two years
|
Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy. |
Up to approximately two years
|
|
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
大体时间:Up to approximately two years
|
Human metabolites of HMPL-760 when co-administered with R-GemOx |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
大体时间:Up to approximately two years
|
maximum concentration in steady-state (Cmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
大体时间:Up to approximately two years
|
time to maximum concentration in steady-state (Tmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
大体时间:Up to approximately two years
|
Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
大体时间:Up to approximately two years
|
The rate at which the drug is eliminated from the body (CL/F) (if applicable ) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
大体时间:Up to approximately two years
|
The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable) |
Up to approximately two years
|
合作者和调查者
赞助
调查人员
- 首席研究员:Weili Zhao、Ruijin Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2025-760-00CH1
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.